Athira Pharma, Inc. (ATHA)

NCM – Real vaqt narxi. Valyuta: USD

6.75

-0.44 (-6.12%)

Yopilishda: Jan 9, 2026, 4:00 PM EDT

18.12.2025

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Athira Pharma Inc. (NASDAQ: ATHA) stock is trading higher on Thursday, with a session volume of 57.29 million compared to the average volume of 30.94 thousand as per data from Benzinga Pro.

18.12.2025

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

18.12.2025

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

In a remarkable pivot, Athira Pharma has a deal to test a promising breast cancer drug and landed $90 million in upfront funding from investors.

18.12.2025

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations

07.08.2025

Athira (ATHA) Q2 Loss Narrows 74%

Athira Pharma (ATHA -2.38%), a biopharmaceutical company developing drugs for neurodegenerative diseases, released its second quarter results on August 7, 2025. The update centered on its cost containment, strategic pipeline refocus, and progress with its lead candidate, ATH-1105.

Videolar

No Data

There is no data to display

Press-relizlar

18.12.2025

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations

Athira Pharma, Inc. (ATHA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Athira Pharma, Inc. (ATHA)

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Athira (ATHA) Q2 Loss Narrows 74%

Videolar

No Data

Press-relizlar

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Athira (ATHA) Q2 Loss Narrows 74%

Videolar

No Data

Press-relizlar

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Search stocks

Athira Pharma, Inc. (ATHA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Athira Pharma, Inc. (ATHA)

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Athira (ATHA) Q2 Loss Narrows 74%

Videolar

No Data

Press-relizlar

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Athira (ATHA) Q2 Loss Narrows 74%

Videolar

No Data

Press-relizlar

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million